ALISO VIEJO, Calif.--(BUSINESS WIRE)--AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that it has received a “Notice of Allowance” from the United States Patent and Trademark Office (USPTO) announcing that it intends to grant the Company a new patent, extending the period of commercial exclusivity for its lead drug candidate Zenvia™ well into 2025. Upon issuance, U.S. patent application number 11/035,213 titled “Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders” will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA). AVANIR’s low-dose quinidine formulation of Zenvia met its primary efficacy endpoint in the recently announced confirmatory Phase III STAR trial in PBA. There are currently no FDA approved treatments for PBA.
